Skip to content

Study · Randomized controlled trial · 2022

10 results

Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.

Yang W, Dong X, Li Q, Cheng Z, Yuan G, Liu M, Xiao J, Gu S, Niemoeller E, Chen L, Ping L, Souhami E

Diabetes, obesity & metabolism12 May 2022Cited by 27 (Europe PMC)

PMID35441412 (opens in a new tab)DOI10.1111/dom.14722 (opens in a new tab)PepBankPUB-35441412
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Asian Pacific adults with diabetes, adding lixisenatide to insulin glargine reduced HbA1c more than insulin glargine alone.

    In plain wordsIn adults with diabetes, adding lixisenatide reduced HbA1c more than insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c reduction
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −21 mmol/mol
    iGlarLixi
    HbA1c change
    −1.9%
    iGlarLixi
    HbA1c change
    −16 mmol/mol
    iGlar
    HbA1c change
    −1.4%
    iGlar

    Source sentences

    Summary
    After 24 weeks, greater reductions in HbA1c from baseline (67 mmol/mol; 8.3%) were seen with iGlarLixi (-21 mmol/mol; -1.9%) compared with iGlar (-16 mmol/mol; -1.4%; P < 0.0001) and Lixi (-10 mmol/mol; -0.9%; P < 0.0001).
    1 context sentence
    Summary · context
    To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin with or without a second oral antihyperglycaemic drug (OAD).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Asian Pacific adults with diabetes, HbA1c target attainment was 79% with iGlarLixi versus 60% with insulin glargine.

    In plain wordsIn adults with diabetes, more reached the HbA1c target with added lixisenatide than with insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHbA1c target attainment
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Target attainment
    79%
    iGlarLixi
    Target attainment
    60%
    iGlar

    Source sentences

    Summary
    Greater proportions of participants achieved HbA1c <53 mmol/mol (<7%) with iGlarLixi versus iGlar or Lixi (79%, 60% and 30%, respectively),
    1 context sentence
    Summary · context
    To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin with or without a second oral antihyperglycaemic drug (OAD).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Asian Pacific adults with diabetes, iGlarLixi improved composite HbA1c targets including weight and hypoglycaemia versus insulin glargine.

    In plain wordsIn adults with diabetes, added lixisenatide improved combined glucose, weight and hypoglycaemia targets versus insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseComposite glycemic targets
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Greater proportions of participants achieved HbA1c <53 mmol/mol (<7%) with iGlarLixi versus iGlar or Lixi (79%, 60% and 30%, respectively), overall and as composite endpoints including weight and hypoglycaemia.
    1 context sentence
    Summary · context
    To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin with or without a second oral antihyperglycaemic drug (OAD).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In Asian Pacific adults with diabetes, iGlarLixi improved postprandial glucose versus insulin glargine.

    In plain wordsIn adults with diabetes, added lixisenatide improved glucose after meals versus insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedTwo-hour postprandial glucose
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    iGlarLixi improved 2-hour postprandial glucose versus iGlar and Lixi
    1 context sentence
    Summary · context
    To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin with or without a second oral antihyperglycaemic drug (OAD).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In Asian Pacific adults with diabetes, iGlarLixi mitigated weight gain versus insulin glargine, with a difference of -1.1 kg.

    In plain wordsIn adults with diabetes, added lixisenatide reduced weight gain versus insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Weight difference
    −1.1 kg
    versus iGlar

    Source sentences

    Summary
    iGlarLixi improved 2-hour postprandial glucose versus iGlar and Lixi and mitigated the weight gain seen with iGlar (least squares mean difference -1.1 kg; P < 0.0001).
    1 context sentence
    Summary · context
    To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin with or without a second oral antihyperglycaemic drug (OAD).
  6. 06HumanRandomized controlled trialSafety outcome

    In Asian Pacific adults with diabetes, documented hypoglycaemia was similar with iGlarLixi and insulin glargine, at 3.38 events per participant-year.

    In plain wordsIn adults with diabetes, hypoglycaemia rates were similar with added lixisenatide and insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    No significant changeDocumented hypoglycaemia
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Hypoglycaemia rate
    3.38 events per participant-year
    both arms

    Source sentences

    Summary
    Documented ≤3.9 mmol/L (≤70 mg/dL) hypoglycaemia was similar between iGlarLixi and iGlar (both 3.38 events per participant-year).
    1 context sentence
    Summary · context
    To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin with or without a second oral antihyperglycaemic drug (OAD).
  7. 07HumanNon-randomized trialEfficacy outcome

    In Asian Pacific adults with diabetes, HbA1c fell by 10 mmol/mol or 0.9% with lixisenatide alone after 24 weeks.

    In plain wordsIn adults with diabetes, HbA1c decreased from baseline with lixisenatide alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c change with lixisenatide alone
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    HbA1c change from baseline
    −10 mmol/mol
    Lixi
    HbA1c change from baseline
    −0.9%
    Lixi

    Source sentences

    Summary
    After 24 weeks, greater reductions in HbA1c from baseline (67 mmol/mol; 8.3%) were seen with iGlarLixi (-21 mmol/mol; -1.9%) compared with iGlar (-16 mmol/mol; -1.4%; P < 0.0001) and Lixi (-10 mmol/mol; -0.9%; P < 0.0001).
    1 context sentence
    Summary · context
    To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin with or without a second oral antihyperglycaemic drug (OAD).
  8. 08HumanNon-randomized trialEfficacy outcome

    In Asian Pacific adults with diabetes, 30% receiving lixisenatide alone achieved HbA1c below 7%.

    In plain wordsIn adults with diabetes, 30% receiving lixisenatide alone reached the HbA1c target.

    Peptide
    Lixisenatide
    Outcome
    Not applicableHbA1c target with lixisenatide alone
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Proportion achieving HbA1c <7%
    30%
    Lixi

    Source sentences

    Summary
    Greater proportions of participants achieved HbA1c <53 mmol/mol (<7%) with iGlarLixi versus iGlar or Lixi (79%, 60% and 30%, respectively),
    1 context sentence
    Summary · context
    To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin with or without a second oral antihyperglycaemic drug (OAD).
  9. 09HumanNon-randomized trialSafety outcome

    In Asian Pacific adults with diabetes, nausea occurred in 21% receiving lixisenatide alone.

    In plain wordsIn adults with diabetes, 21% receiving lixisenatide alone reported nausea.

    Peptide
    Lixisenatide
    Outcome
    Not applicableNausea with lixisenatide alone
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Nausea incidence
    21%
    Lixi

    Source sentences

    Summary
    The incidence rates of nausea and vomiting were lower with iGlarLixi (14% and 6%) than Lixi (21% and 11%).
    1 context sentence
    Summary · context
    To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin with or without a second oral antihyperglycaemic drug (OAD).
  10. 10HumanNon-randomized trialSafety outcome

    In Asian Pacific adults with diabetes, vomiting occurred in 11% receiving lixisenatide alone.

    In plain wordsIn adults with diabetes, 11% receiving lixisenatide alone reported vomiting.

    Peptide
    Lixisenatide
    Outcome
    Not applicableVomiting with lixisenatide alone
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Vomiting incidence
    11%
    Lixi

    Source sentences

    Summary
    The incidence rates of nausea and vomiting were lower with iGlarLixi (14% and 6%) than Lixi (21% and 11%).
    1 context sentence
    Summary · context
    To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin with or without a second oral antihyperglycaemic drug (OAD).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT03798054

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

Sanofin = 87815 Feb 2019 to 1 Mar 2021

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 19 Jul 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.